Anti-UV Technology Using Synthetic Biology

Extracts produced by this method have applications such as protection against skin damage, protection of physical surfaces against UV damage, and missions to space.

This technology uses extracts produced from yeast transformed with a new anti-UV DNA construct to block ultraviolet (UV) radiation.

The anti-UV DNA construct was prepared using synthetic biology and/or conventional molecular biology. Different genetic sequences, including repair proteins — such as heat shock protein (HSP), energy metabolic proteins, and other up-regulating proteins — and other synthetic gene sequences were used. Read more...


BioCapital accepted to Johnson & Johnson Center for Device Innovation

BioCapital was accepted as one of the 140 nationwide startup companies in the Johnson & Johnson Center for Device Innovation at the Texas Medical Center (JLABS).  BioCapital also submitted its patented glucose detection technology as part of the "QuickFire Challenge".  The Challenges goals include entries designed to prevent obesity.  BioCapital highlighted our patented technology that measures the insulin and glucose levels of a patient's blood for the early detection of Type 2 Diabetes.  

Selection for admission to JLABs-TMC provides BioCapital with lab space and access to their extensive research laboratory including access to the device prototyping lab, and mentorship and coaching from Johnson & Johnson Medical devices experts including the world renowned Billy Cohn.  

Additionally, Johnson & Johnson Innovation has partnered with angelMD, an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners to provide the winning solution an additional $100,000 investment from its catalyst fund, plus angelMD will feature the top finalists on its web platform for syndicate partners to invest up to an additional $250,000.


BioCapital to work with NASA

BioCapital is in discussions with NASA, licensor of one of the anti-UV patents, and initiated steps to stimulate broaden joint efforts to commercialize that intellectual property.  Plans are to have BioCapital publish an article in NASA's Tech Briefs,